Kuros Biosurgery AG, has announced that it has regained rights to a number of trauma and spine product candidates that were previously licensed to Baxter International Inc.
Kuros’ regained rights include the following product candidates:
• KUR-111 - KUR-111 has met its primary efficacy endpoint demonstrating non-inferiority to autograft in a 183 patient Phase II study in tibial plateau fracture patients.
• KUR-113 - KUR-113 is in an ongoing Phase II study evaluating the efficacy and safety of KUR-113 as an adjunct to the standard of care in the treatment of patients with acute open tibial shaft fractures. The 6 month results are reported in a separate press release issued by Kuros.
• KUR-115 - which is being prepared for clinical studies in spinal fusion patients.
Didier Cowling, Chief Executive Officer of Kuros, commenting on today’s announcement said: “We now have rights to a portfolio of late stage clinical products with significant clinical efficacy and safety data following Kuros having regained the rights to these product candidates from Baxter. We look forward to developing them further so that both patients and clinicians can benefit from the advantages that they could offer in the treatment of a number of trauma and spine indications.”
Baxter and Kuros continue to be partners in the development of KUR-211, a product for the treatment of chronic wounds which is currently in a large pan European Phase II study involving patients with diabetic foot ulcers.
Kuros and Baxter International Inc. signed their original collaboration and license agreement in 2005.